Strategic Collaborations Plexium's premier TPD platform focuses on monovalent degraders and molecular glues, backed by the DELTA Discovery platform and ultra-high throughput screening that has advanced multiple clinical-stage degraders. This presents a path for pharma and biotech partners to co-develop or license degraders against difficult targets, with opportunities for joint discovery programs, target validation support, or licensing of programs.

Discovery Services Leverage Plexium as a CRO-like partner for target expansion and screening, tapping their uHTS cell-based platform to broaden the druggable space in client programmes. Potential services include target validation, assay development, hit discovery, lead optimization support, and external collaboration using the DELTA Discovery platform.

Oncology Focus Plexium has oncology-oriented degraders and has showcased work at AACR 2025. With clinical-stage programs and a growing leadership team, there is a pathway to partner on cancer targets, licensing opportunities for lead degraders, or co-development deals aligned with high unmet medical needs.

Funding Capacity With revenue in the tens of millions and total funding around sixty million dollars, Plexium has financial runway for milestone-driven collaborations. This can enable structured deal terms, upfronts, milestones, and option-based partnerships, reducing client risk while granting access to their platform and pipeline.

Market Engagement Active industry engagement evidenced by AACR presentations and leadership updates signals readiness to scale partnerships. Clients can leverage Plexium's leadership network and clinical development expertise to accelerate deals, shape regulatory strategy, and tap into their ecosystem.